Allopurinol in Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis

Ain Shams University

Status

Completed

Conditions

Endoscopic Retrograde Cholangiopancreatography

Treatments

Drug: Allopurinol

Study type

Interventional

Funder types

Other

Identifiers

NCT02992652

937

Details and patient eligibility

About

The investigators evaluated the role of allopurinol in prevention of post-ERCP pancreatitis.
100 Egyptian patients who were candidates for ERCP were included and divided into two groups. Group 1 (study group) included 50 patients who received two doses of allopurinol 300 mg each, 15 hours and 3 hours before ERCP and Group 2 (control group) included 50 patients who did not receive allopurinol prophylaxis.

Full description

A diagnosis of procedure-related pancreatitis was based on an increased serum amylase level greater than three times the upper normal limits, associated with abdominal pain requiring analgesics and persisting for at least 24 hours after the procedure.

Enrollment

100 patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients who were going to be subjected to ERCP due to different causes

Exclusion criteria

Patients with clinically evident acute pancreatitis or hyperamylesemia (≥150 IU/L) before the procedure.
Current or recent use of allopurinol (within the last 48 hours).
Hypersensitivity to allopurinol or hydro-soluble contrast solutions.
Current use of drugs with a known interaction with allopurinol, including cyclophosphamide, chlorpropamide, azathioprine, mercaptopurines, or probenecid.
NSAIDS intake within a week prior to assessment.
Previous endoscopic or surgical sphincterotomy.
Those with severe co-morbid conditions.
Female patients with a known or suspected pregnancy and/or lactation.